These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 18464745

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nyström F, Hägg A, Lind L.
    J Hypertens; 2002 Apr; 20(4):657-63. PubMed ID: 11910301
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R, Kahan T, Malmqvist K, Ring M, Edner M.
    Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Hallberg P, Lind L, Billberger K, Michaelsson K, Karlsson J, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nyström F, Liljedahl U, Syvänen AC, Melhus H.
    Clin Cardiol; 2004 Mar; 27(3):169-73. PubMed ID: 15049387
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Müller-Brunotte R, Kahan T, López B, Edner M, González A, Díez J, Malmqvist K.
    J Hypertens; 2007 Sep; 25(9):1958-66. PubMed ID: 17762662
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Malmqvist K, Ohman KP, Lind L, Nyström F, Kahan T.
    J Cardiovasc Pharmacol; 2003 Dec; 42(6):719-26. PubMed ID: 14639093
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.
    Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, Nyström F, Hägg A, Lind L, Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial.
    J Hypertens; 2001 Oct; 19(10):1783-7. PubMed ID: 11593098
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan.
    Jiang S, Hsu YH, Venners SA, Zhang Y, Xing H, Wang X, Xu X.
    J Hypertens; 2011 May; 29(5):890-5. PubMed ID: 21346624
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy.
    Hallberg P, Lind L, Michaëlsson K, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nyström F, Liljedahl U, Syvänen AC, Melhus H.
    BMC Cardiovasc Disord; 2003 Sep 18; 3():11. PubMed ID: 13678427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.